AU2023221393A1 - Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa - Google Patents

Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa Download PDF

Info

Publication number
AU2023221393A1
AU2023221393A1 AU2023221393A AU2023221393A AU2023221393A1 AU 2023221393 A1 AU2023221393 A1 AU 2023221393A1 AU 2023221393 A AU2023221393 A AU 2023221393A AU 2023221393 A AU2023221393 A AU 2023221393A AU 2023221393 A1 AU2023221393 A1 AU 2023221393A1
Authority
AU
Australia
Prior art keywords
administration period
subject
months
prior
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023221393A
Other languages
English (en)
Inventor
Andrea MAES
Christina Ramirez
Ariel Teper
Marcela VERGARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of AU2023221393A1 publication Critical patent/AU2023221393A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023221393A 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa Pending AU2023221393A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
US63/310,751 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
AU2023221393A1 true AU2023221393A1 (en) 2024-08-15

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023221393A Pending AU2023221393A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Country Status (11)

Country Link
US (1) US20250144116A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479059A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508359A (cg-RX-API-DMAC7.html)
KR (1) KR20240148350A (cg-RX-API-DMAC7.html)
CN (1) CN118695864A (cg-RX-API-DMAC7.html)
AU (1) AU2023221393A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244131A1 (cg-RX-API-DMAC7.html)
GB (1) GB2630719A (cg-RX-API-DMAC7.html)
IL (1) IL314769A (cg-RX-API-DMAC7.html)
MX (1) MX2024009995A (cg-RX-API-DMAC7.html)
WO (1) WO2023159120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA3244131A1 (en) 2023-08-24
EP4479059A4 (en) 2026-01-28
GB202412566D0 (en) 2024-10-09
WO2023159120A1 (en) 2023-08-24
KR20240148350A (ko) 2024-10-11
JP2025508359A (ja) 2025-03-26
MX2024009995A (es) 2024-08-22
US20250144116A1 (en) 2025-05-08
GB2630719A (en) 2024-12-04
EP4479059A1 (en) 2024-12-25
IL314769A (en) 2024-10-01
CN118695864A (zh) 2024-09-24

Similar Documents

Publication Publication Date Title
US20250144116A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
US20220152056A1 (en) Methods and compositions for treating various disorders
US20250049813A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
Camras et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery
JP2022001592A (ja) 代謝障害を治療するための組成物および方法
US11998553B2 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
US20230338367A1 (en) Treatment of prurigo nodularis
KR20240004691A (ko) 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
JP2024133735A (ja) Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP2013199506A (ja) 処置方法
CA2555316A1 (en) Combined pharmaceutical composition
WO2020014342A1 (en) Treatment of the pruritic symptoms of liver disease
KR20200066664A (ko) 세균 감염증을 치료하는 방법
US20260108483A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
CN121796375A (zh) 用于预防和治疗糖尿病心肌病的化合物及其应用
HK40003409A (en) Treatment of prurigo nodularis